Injectable Drug Delivery MarketThe global injectable drug delivery market is estimated to be valued at USD 49.44 billion in 2024, with strong growth expectations due to advancements in healthcare, ...

The global Insulin Delivery Devices Market was valued at USD 30.9 billion in 2022 and is expected to grow significantly, ...

CNET’s expert staff reviews and rates dozens of new products and services each month, building on more than a quarter century of expertise.

Continuous glucose monitoring (CGM) is wearable technology used to monitor glucose levels at all times. A sensor is placed beneath the arm's or belly's skin and reads interstitial glucose, which is ...

Eli Lilly, the world’s biggest drugmaker by market value, reported higher-than-expected quarterly profit and issued a bullish earnings forecast. Sales of weight-loss drug Zepbound and diabetes ...

Eli Lilly LLY-N on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing investor agitation about signs of weakness in sales of the drugs.

Samsung has since clarified that Bluetooth support for the S Pen is, in fact, gone. According to Samsung, the blog post was made in error, and the Galaxy S25 Ultra will not offer any Bluetooth ...

In the kitchen of her South St. Paul home, Abigail Turner prepares the insulin she uses to manage her type 1 diabetes last February. Minnesota announced a final settlement Monday with the last of ...

A satirical X post saying the three major insulin manufacturers in the United ... A spokesperson for Lilly said in a Jan. 23 email: “These statements are categorically false.

(ABC 6 News) – On Monday, Attorney General Keith Ellison announced a settlement with Novo Nordisk that let’s Minnesotans buy its insulin products ... were reached Eli Lilly and Sanofi in ...

In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price target of $1,146.00. The company’s shares closed ...

The AG's office filed a lawsuit in 2018 against insulin manufacturers Eli Lilly, Sanofi and Novo Nordisk, alleging the companies deceptively raised the price of insulin. In 2024, the AG's office ...